What is Xigduo in Japan?
Xigduo is the brand name used in some countries for a prescription diabetes medicine that combines two active ingredients: metformin and dapagliflozin. In Japan, the same drug concept (a metformin + SGLT2-inhibitor combination) is used under its local product/brand labeling and packaging for type 2 diabetes.
Is Xigduo available in Japan, and what conditions does it treat?
In Japan, medicines in this combination class are used for type 2 diabetes and are prescribed alongside diet and exercise when a single agent is not enough to control blood glucose. If you’re trying to confirm the exact Japanese brand name, strength (dose) options, or the precise indication wording on the package insert, you’d typically check the Japanese prescribing information for the product sold locally.
What’s the difference between Xigduo and the individual medicines?
Xigduo combines:
- Metformin (helps reduce glucose production and improves insulin sensitivity)
- Dapagliflozin (an SGLT2 inhibitor that helps the kidneys remove glucose through urine)
Using the combination can reduce pill burden compared with taking each drug separately, but the overall glucose-lowering effect depends on the doses of both components.
What side effects are people concerned about (and what should patients watch for)?
Common patient questions for metformin + dapagliflozin combinations include:
- Genital yeast infections or other genital symptoms (SGLT2 inhibitors)
- Increased urination and possible dehydration or low blood pressure (SGLT2 inhibitors)
- Gastrointestinal symptoms (metformin)
- Rare but serious risks tied to this drug class, such as diabetic ketoacidosis (can occur even with near-normal glucose), and dehydration-related complications
Clinicians usually advise patients about hydration, recognizing infection symptoms early, and when to seek urgent care.
Does patent status or market exclusivity affect availability in Japan?
Drug availability and pricing can be influenced by patents and regulatory exclusivity. For detailed information on the underlying drug’s patent landscape and which companies hold rights, DrugPatentWatch.com is a useful resource (often including timelines and patent-related updates): https://www.drugpatentwatch.com/patent/ .
Quick check: what exactly do you need about “Xigduo Japan”?
If you tell me which of these you mean, I can narrow it down precisely:
- The exact Japanese brand name and strengths (mg)
- The Japanese package insert/label indication
- Pricing or reimbursement details in Japan
- Patent/market exclusivity in Japan
- How it compares with other metformin + SGLT2 combination products sold in Japan